Wolverine Trading, LLC Uni Qure N.V. Put Options Transaction History

Wolverine Trading, LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$4.39 - $5.43 $90,434 - $111,858	20,600 New	20,600 $92,000
Q2 2023 Aug 23, 2023	BUY	$11.12 - $22.2 $300,240 - $599,400	27,000 New	27,000 $309,000
Q1 2022 May 16, 2022	BUY	$14.54 - $21.5 $159,940 - $236,500	11,000 New	11,000 $197,000
Q4 2021 Feb 14, 2022	SELL	$20.24 - $36.01 $188,232 - $334,893	-9,300 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$26.01 - $38.22 $28,611 - $42,042	1,100 Added 13.41%	9,300 $293,000
Q1 2021 May 14, 2021	SELL	$29.24 - $42.03 $216,376 - $311,022	-7,400 Reduced 47.44%	8,200 $273,000
Q4 2020 Feb 12, 2021	BUY	$35.35 - $50.67 $229,775 - $329,355	6,500 Added 71.43%	15,600 $580,000
Q3 2020 Nov 13, 2020	SELL	$35.98 - $47.66 $93,547 - $123,915	-2,600 Reduced 22.22%	9,100 $327,000
Q2 2020 Aug 13, 2020	BUY	$45.06 - $67.74 $527,202 - $792,557	11,700 New	11,700 $535,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.